Who is sponsoring NCT01834274?

NCT01834274 is sponsored by Takeda.

What condition does NCT01834274 study?

NCT01834274 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01834274?

Interventions: Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin.

What is the status of NCT01834274?

NCT01834274 is currently TERMINATED.

Last reviewed 2015-08-26 · How we verify

A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes

NCT01834274 Phase 3 TERMINATED Results posted

The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	TERMINATED
Enrolment	96
Start date	2013-06
Completion	2014-03

Conditions

Diabetes Mellitus, Type 2

Interventions

Fasiglifam (TAK-875)
Fasiglifam (TAK-875) Placebo
Sitagliptin
Sitagliptin Placebo
Metformin

Primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) — Baseline and Week 24
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit relative to Baseline. A negative change from Baseline indicated improvement.

Countries

United States, Argentina, Canada, Croatia, Hungary, Malaysia, Peru, Philippines, Poland, Russia, South Africa, Thailand, Ukraine